CD19 and plasma cell myeloma: Shi Xiaolan et al (68), conducted a single-center, phase II clinical trial (NCT03455972) to evaluate the safety and efficacy of anti-CD19/BCMA dual-targeted CAR-T therapy combined with lenalidomide maintenance following autologous stem cell transplantation (ASCT) in patients with high-risk newly diagnosed multiple myeloma (NDMM).